?-Vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice
- 1 October 1988
- journal article
- conference paper
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 72 (3) , 213-233
- https://doi.org/10.1007/bf01243421
Abstract
Biochemical and pharmacological effects ofγ-vinyl GABA (Vigabatrin®, GVG), an irreversible enzyme-activated inhibitor of 4-aminobutyrate: 2-oxoglutarate aminotransferase (EC 2.6.1.19; GABA-T), were measured in mice. This anticonvulsant produced a time- and dose-dependent elevation of the GABA, phenylalanine and lysine contents of cortical tissue and simultaneously decreased glutamate, aspartate and alanine levels. In addition, GVG caused a biphasic change in glutamine concentrations (a decline 1–4 hours after administration, followed 20 hours later by an increase). Moreover, we found a new, as yet unidentified amino acid in the brain eluting with the same retention time as α-aminoadipic acid from an HPLC cation-exchange column. The level of this novel chemical entity was greatly increased by GVG 20 hours after injection of the drug. At all tested intervals between 1 and 60 hours after injection, GVG was ineffective against maximal electroshock. The GABA-T inhibitor dose-dependently protected mice against isoniazid-induced seizures, simultaneously causing an increase in brain GABA concentrations. However, this apparent correlation applied only until 4 hours after treatment. To better define the anticonvulsant profile of GVG, groups of mice were treated, 1, 2, 4, and 24 hours prior to challenge with convulsant doses of strychnine, pentetrazole (PTZ), and picrotoxin, and brain amino acid levels, including brain concentrations of GVG, were measured. In all instances, the time dependency of the anticonvulsant effects of GVG and of increases in brain GABA levels differed. Amino acid concentrations in animals treated only with GVG were similar to those in animals given GVG and a chemical convulsant. GVG showed no selectivity for seizures produced by impairment of GABA-ergic neurotransmission. Although GVG is an effective GABA-T inhibitor, it apparently affects several other pyridoxal-phosphate-dependent cerebral enzymes and/or interacts with other neurotransmitter systems as well.This publication has 23 references indexed in Scilit:
- Does pipecolic acid interact with the central GABA-ergic system?Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1986
- Double‐Blind, Placebo‐Controlled Study of Vigabatrin (Gamma‐Vinyl GABA) in Drug‐Resistant EpilepsyEpilepsia, 1986
- The specific protective effect of diazepam and valproate against isoniazid-induced seizures is not correlated with increased GABA levelsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- The Use of Inhibitors of GABA‐Transaminase for the Determination of GABA Turnover in Mouse Brain Regions: An Evaluation of Aminooxyacetic Acid and GabaculineJournal of Neurochemistry, 1982
- Effect of γ-vinyl GABA on bicuculline-induced seizuresNeuropharmacology, 1981
- Seizure Protection and Increased Nerve-Terminal GABA: Delayed Effects of GABA Transaminase InhibitionScience, 1980
- γ‐VINYL GABA: EFFECTS OF CHRONIC ADMINISTRATION ON THE METABOLISM OF GABA AND OTHER AMINO COMPOUNDS IN RAT BRAINJournal of Neurochemistry, 1979
- Antiepileptic Drug Development: II. Anticonvulsant Drug ScreeningEpilepsia, 1978
- New concepts on the mechanism of action of benzodiazepinesLife Sciences, 1975
- Convulsant drugs: Amino acid antagonism and central inhibitionNeuropharmacology, 1974